Swedish Authorities Muscle in on Industry/Health Service Relationship
18 May 2005ERA News
Corporate “freebies” in terms of sponsorships and gifts provided by pharmaceutical companies to individuals in the medical profession have come under increased scrutiny in Europe recently. Governments and regulators are keen to eradicate what they often perceive to be a diluted form of corruption that has a direct impact on the successful marketing of drugs. Amongst European countries in which authorities have stepped up their enforcement activities concerning pharmaceutical marketing practices and other relationships with healthcare professionals, Sweden offers an example of particularly stringent rules. Linda Horton and Andreas Blomquist, respectively partner and lawyer at Hogan and Hartson’s Brussels office, discuss the recent development of strict rules concerning the Swedish pharmaceutical industry’s dealings with its healthcare sector.